Detalhe da pesquisa
1.
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Cancer
; 121(6): 883-92, 2015 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377507
2.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24933332
3.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
ESMO Open
; 5(1)2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31958290
4.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer
; 19(3): 270-279.e3, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29373274
5.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer
; 112: 126-133, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191585
6.
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Lung Cancer
; 112: 181-187, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191593
7.
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL).
Cancer Res Treat
; 48(4): 1177-1186, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26910471
8.
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
Clin Lung Cancer
; 13(6): 505-9, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22853980